Loading clinical trials...

Mortality Reductions Based on AUD/Heavy Alcohol Use, HIV Risk, and Cardiovascular Risk | Clinical Trials | Clareo Health

ACTIVE_NOT_RECRUITINGNA

Mortality Reductions Based on AUD/Heavy Alcohol Use, HIV Risk, and Cardiovascular Risk

Can a Radical Transformation of Preventive Care Reduce Mortality by 20% in Low Socioeconomic (SES) Populations? Preparatory Work Focusing on Alcohol Use Disorder (AUD)/Heavy Alcohol Use, HIV Risk, and Cardiovascular Risk

NCT05828849•NYU Langone Health

View on ClinicalTrials.gov

Summary

The purpose of this research study is to investigate if a personalized intervention including parts such as navigation (focus on patient outreach efforts, missed and completed encounters), personalization (individual health benefits) and compensation (value health-related costs borne by patients) will help people reduce their chances of dying from preventable causes, including heart attacks, strokes, drinking alcohol, substance abuse, HIV, and other conditions.

Eligibility

Age

35 - 64 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•1. Age 35 to 64
•2. Low SES (≤ $38,000 annual income, based on 2019 20th percentile NYC income, adjusted for family size)
•3. Expected mortality ≥1% per year (based on age, sex, race/ethnicity), with ≥1 of the following contributors:
•1. 10-year cardiovascular risk ≥10% (assessed by ASCVD risk tool)
•2. Heavy alcohol consumption (defined using SAMHSA binge drinking definition, drinking \>4 standard drinks for men and \>3 standard drinks for women on same occasion in past month)
•4. Willing to be navigated to Health and Hospitals Corporation of New York health system.
•5. Ability to provide written informed consent in English or Spanish

Exclusion Criteria

•1. Receives regular care elsewhere than Health and Hospitals Corporation of New York
•2. Already diagnosed with high mortality-condition(s) that are not included in the simulation model.

Locations (1)

NYC H+H/Bellevue

New York, New York, United States

Key Dates

Start Date

June 25, 2024

Primary Completion Date

July 1, 2026

Completion Date

July 1, 2026

Last Updated

March 3, 2026

Enrollment

ACTUAL participants

Conditions

Cardiovascular DiseaseAlcohol Use DisorderHIV RiskSubstance Use Disorders

Interventions

Navigation, compensation, and personalization

BEHAVIORAL

Phenotyping Patients With Alcohol and Cannabis Use Disorders Using the Addictions Neuroclinical Assessment

NCT05855668

Alcohol Use DisorderCannabis Use Disorder

View study

RECRUITINGPHASE3

A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)

NCT07241390

Atherosclerosis Cardiovascular DiseaseChronic Kidney Disease

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 3, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Mortality Reductions Based on AUD/Heavy Alcohol Use, HIV Risk, and Cardiovascular Risk

Inclusion Criteria

Exclusion Criteria

Phenotyping Patients With Alcohol and Cannabis Use Disorders Using the Addictions Neuroclinical Assessment

A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)

Dietary Omega-7 Palmitoleic Acid-Rich Oil on Lipoprotein Metabolism and Satiety in Adults

The Prevalence, Disease Burden and Prognosis of COPD in Patients With Cardiovascular Diseases

OPTImizing CArdiac REhabilitation by REfining Sleep and STress

Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD